CALT Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 22:00):

Stats
Dagens volum	4 760.00
Gjennomsnittsvolum	6 716.00
Markedsverdi	535.11M
EPS	$0 ( 2024-02-21 )
Neste inntjeningsdato	( $-0.140 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.54
ATR14	$0 (0.00%)

Calliditas Therapeutics Korrelasjon

10 Mest positive korrelasjoner
BLPH	0.931
ASLN	0.922
ORTX	0.916
KBAL	0.908
UNCY	0.902
ADMS	0.888
ALBO	0.887
PLPC	0.884
CMPI	0.879
CPTA	0.877

10 Mest negative korrelasjoner
CARA	-0.92
STIM	-0.908
ACNB	-0.906
VEON	-0.902
TVACW	-0.899
CPTN	-0.899
ALEC	-0.898
PCB	-0.896
CBAN	-0.895
BRKL	-0.893

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Calliditas Therapeutics Økonomi

Annual	2023
Omsetning:	$1.21B
Bruttogevinst:	$1.13B (93.62 %)
EPS:	$-8.69

FY	2023
Omsetning:	$1.21B
Bruttogevinst:	$1.13B (93.62 %)
EPS:	$-8.69

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0

FY	2022
Omsetning:	$802.88M
Bruttogevinst:	$787.68M (98.11 %)
EPS:	$-7.78

Financial Reports:

No articles found.

Calliditas Therapeutics

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.